Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03339778
Other study ID # IIS201401-PID
Secondary ID
Status Completed
Phase N/A
First received March 31, 2015
Last updated November 7, 2017
Start date June 2015
Est. completion date September 2017

Study information

Verified date November 2017
Source IMMUNOe Research Centers
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with primary immunodeficiency disorders (PID) on intravenous immunoglobulin (IVIG) treatment may experience adverse events (AEs). Patients who experience AEs on any 10% IVIG solution will be changed to octagam 5% for six infusions to evaluate the potential benefit for reduction of AEs on a lower concentration IVIG product.


Description:

Patients with PID require life long immunoglobulin (Ig) replacement therapy with IVIG being the most common form. As more 10% IVIG products are FDA approved, the older and well characterized 5% IVIG products are becoming less used. Currently, the standard of care for patients who experience AEs on IVIG is to move to a subcutaneous (SCIG) delivery and product. This study will evaluate the AEs on a 10% product and octagam 5%. The study will enroll 15 patients after an AE on any 10% product who will then be infused with octagam 5% for six infusions. AEs will be documented and compared to the 10% product along with changes in biomarkers. The study data may document another therapeutic option for patients who experience AEs - SCIG and octagam 5%.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date September 2017
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender All
Age group 10 Years to 75 Years
Eligibility Inclusion Criteria:

- Participants, or legal guardians with assent by underage children, will sign informed consent/assent and are willing to comply with all aspects of the study

- Diagnosis of CVID according IUIS Expert Committee

- Participants on a 10% product who experience AEs

- Ages between 10 and 75 years of age

- Participants on 10% IVIG therapy every 21±3 days or 28±3 days between 300 - 800 mg/Kg body weight

Exclusion Criteria:

- Acute infection requiring antibiotic therapy within 7 days prior to visit 1

- Presence of any condition that is likely to interfere with the evaluation of the study medication or satisfactory conduct of the trial

- History of anaphylactic or severe systemic reactions to human immunoglobulin

- IgA deficient patients with antibodies against IgA and a history of hypersensitivity

- Females who are pregnant or lactating

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
IMMUNOe Research Centers

References & Publications (4)

Deane S, Selmi C, Naguwa SM, Teuber SS, Gershwin ME. Common variable immunodeficiency: etiological and treatment issues. Int Arch Allergy Immunol. 2009;150(4):311-24. doi: 10.1159/000226232. Epub 2009 Jul 1. Review. Erratum in: Int Arch Allergy Immunol. 2010;151(4):284. Dosage error in article text. — View Citation

Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarström L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J; International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol. 2007 Oct;120(4):776-94. — View Citation

Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol. 2011 Jun;164 Suppl 2:2-5. doi: 10.1111/j.1365-2249.2011.04387.x. Review. — View Citation

Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents. 2011 May;37(5):396-404. doi: 10.1016/j.ijantimicag.2010.11.027. Epub 2011 Jan 26. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The change in the number of AEs post-infusion between any 10% IVIG product and octagam 5% AEs will be documented at screening and up to 72 hours post-infusion for six infusions up to 24 weeks
Secondary The change in levels of inflammatory biomarkers associated with AEs between any 10% IVIG and octagam 5% Levels will be documented at screening and up to 72 hours post-infusion for six infusions up to 24 weeks
Secondary Safety Evaluations (complete blood count [CBC]) CBC Screening and prior to each infusion (six infusions total) up to 24 weeks
Secondary Safety evaluations (Complete Metabolic profile[CMP]) CMP Screening and prior to each infusion (six infusions total) up to 24 weeks
Secondary Safety evaluations (IgG trough level) IgG trough level Screening and prior to last infusion up to 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT04561115 - A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency Phase 3
Recruiting NCT06355323 - Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France N/A
Completed NCT04566692 - A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency Phase 4
Completed NCT01465958 - Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency Phase 4
Completed NCT01581593 - Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Phase 3
Completed NCT02881437 - IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia Phase 4
Recruiting NCT06092528 - Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency N/A
Active, not recruiting NCT03576742 - Severe Immune Cytopenia Registry Www.Sic-reg.Org
Completed NCT03907241 - CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL Phase 3
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Completed NCT02806986 - Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency Phase 3
Enrolling by invitation NCT00895271 - Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Recruiting NCT03206099 - NIAID Centralized Sequencing Protocol
Completed NCT02503293 - A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push Phase 4
Recruiting NCT03610802 - Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
Completed NCT03815357 - What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?
Completed NCT02269163 - Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% Phase 3
Terminated NCT03733249 - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Phase 1/Phase 2
Not yet recruiting NCT02123615 - ASIS for GAMMAGARD in Primary Immunodeficiency Phase 1/Phase 2
Completed NCT02604810 - Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency Phase 3